Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 24 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

8%

2 trials in Phase 3/4

Results Transparency

7%

1 of 14 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

11Total
Not Applicable (9)
P 4 (2)

Trial Status

Completed14
Unknown4
Recruiting3
Suspended2
Active Not Recruiting1

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 14 completed trials

Clinical Trials (24)

Showing 20 of 20 trials
NCT06219720RecruitingPrimary

The Texas Interprofessional Pharmacogenomics (IPGx)

NCT04154553RecruitingPrimary

Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure

NCT05508763Active Not RecruitingPrimary

Personalised Therapeutics @LUMC

NCT06498167Recruiting

Active Pharmacovigilance Study of the Medicine Rinvoq™ (Upadacitinib)

NCT03093818Not ApplicableCompletedPrimary

PREemptive Pharmacogenomic Testing for Preventing Adverse Drug REactions

NCT02134587Not ApplicableCompletedPrimary

Educational Intervention in Pharmacovigilance for Hospital Health Professionals

NCT04553107Not ApplicableCompleted

Reducing Costs by Deprescribing Medications

NCT01946919CompletedPrimary

Post-Marketing Surveillance of the Cinepazide Maleate Injection: a Real World Study

NCT03943524Not ApplicableSuspended

Drug Interactions in Outpatients.

NCT05224804CompletedPrimary

Pharmacists' Knowledge and Attitudes About ADRs Reporting and Pharmacovigilance Practice in Egyptian Hospitals

NCT02559960Suspended

Post-marketing Safety Surveillance of Breviscapine Powder-Injection : a Registry Study

NCT02297126Not ApplicableCompletedPrimary

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT04568668Not ApplicableUnknown

Evaluating ActionADE in Reducing Adverse Drug Reactions

NCT03354845Not ApplicableUnknown

Deprescribing of Symptomatic Medications in Rehabilitative or Subacute Care Patients

NCT01679964Phase 4Completed

Sustained Virological Suppression and Improvement of Adverse Events of Switching to Raltegravir Study

NCT02888834CompletedPrimary

Serious Adverse Drug Reaction and Their Preventability

NCT02838212CompletedPrimary

Adverse Drug Reactions With Fatal Outcome

NCT02159209Completed

The Drug Induced Renal Injury Consortium

NCT02094638CompletedPrimary

Post-Marketing Surveillance of the Tanreqing Injection: a Real World Study

NCT01872520CompletedPrimary

Post-marketing Safety Surveillance of the Injection of DanShenDuoFenSuanYan A Real World Study

Scroll to load more

Research Network

Activity Timeline